6533b82dfe1ef96bd1291f33

RESEARCH PRODUCT

Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience

Giuseppe ColucciVincenzo AdamoM. VenturiniS. De PlacidoDario GiuffridaDavide DondiPierfranco ConteG. MasciNicola GebbiaFrancesco CognettiGiuseppina Rosaria Rita Ricciardi

subject

OncologyCancer ResearchSettore MED/06 - Oncologia MedicaReceptor ErbB-2receptormedicine.medical_treatmentreceptorsGuidelineClinical practicechemotherapyAntineoplastic Combined Chemotherapy ProtocolsestrogenMedicineStage (cooking)Triple-negative breast cancerAdjuvant therapy Clinical practice Guidelines Italy National register Triple-negative breast cancer --------------------------------------------------------------------------------Middle AgedCombined Modality TherapyReceptors EstrogenItalyOncologyChemotherapy AdjuvantHormonal therapyFemaleReceptors Progesteronemedicine.medical_specialtyNational registerBreast NeoplasmsprogesteroneGuidelinesAdjuvant therapyBreast canceradjuvantTriple-negative breast canceradjuvant therapy; clinical practice; guidelines; italy; national register; triple-negative breast cancer; aged; antineoplastic combined chemotherapy protocols; breast neoplasms; chemotherapy adjuvant; combined modality therapy; female; humans; italy; middle aged; radiotherapy adjuvant; receptor erbb-2; receptors estrogen; receptors progesterone; retrospective studiesInternal medicineAdjuvant therapyHumansradiotherapyAgedRetrospective StudiesChemotherapybusiness.industryTriple-negative breast cancer --------------------------------------------------------------------------------medicine.diseaseRadiation therapyAged Antineoplastic Combined Chemotherapy Protocols; therapeutic use Breast NeoplasmsRadiotherapy AdjuvantObservational studybusinesserbb-2

description

Abstract Aims Triple-negative breast cancers (TNBCs) lack expression of oestrogen, progesterone, and Human Epidermal Growth Factor 2 receptors. The NEMESI study described current Italian treatment practices in patients with operable, early-stage breast cancer (EBC). Patients and methods Retrospective, observational study involving 63 Italian oncology centres. Eligible patients were aged ⩾18 years with EBC (stage I–II) who had undergone surgery, received ⩾1 cycle of adjuvant chemotherapy and/or adjuvant hormonal therapy and attended an oncology centre between 1 January 2008 and 30 June 2008. This subanalysis focused on patients with TNBC. Variables evaluated included: demographic data/clinical characteristics; tumour characteristics; adjuvant therapy; compliance to chemotherapy. Continuous variables were summarised using descriptive statistics. Results Of 1894 patients in the NEMESI study, 185 patients (9.8%) had TNBC. At diagnosis, 98 patients were aged 50–70 years and 114 were post-menopausal. Tumours were subcategorised as pT1mic/pT1a/pT1b/pT1c in 108 patients and pT2/pT3/pT4b in 77 patients. Mean tumour size was 2.1 cm, tumours were highly undifferentiated in 144 patients and 128 patients were pNO. 179 patients received adjuvant chemotherapy; anthracyclines with or without taxanes were commonly used. 145 patients received radiotherapy. Conclusions Adherence of Italian clinical practice to International Guidelines in the management of early-stage TNBC is satisfactory.

yearjournalcountryeditionlanguage
2011-01-01
http://hdl.handle.net/11588/422173